Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV F Nanoparticle Vaccine in Healthy Children
NCT02296463Phase 1Completed
- Sponsor
- Novavax
- Start
- Nov 2014
- Primary completion
- Sep 2015
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSV F vaccine + aluminum phosphate in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Novavax. Primary endpoints: Solicited Local and Systemic Adverse Events and Serum IgG Antibody Levels Specific for F Protein Antigen. Started Nov 2014; status: completed.
02
Drugs
RSV F vaccine + aluminum phosphate
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02296463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296463.